Abstract | PURPOSE: EXPERIMENTAL DESIGN: We conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanomas harboring KIT mutations or amplification: (A) those refractory or intolerant to a prior KIT inhibitor; and (B) those with brain metastases. The primary endpoint was 4-month disease control rate. Secondary endpoints included response rate, time-to-progression ( TTP), and overall survival (OS). A Simon two-stage and a single-stage design was planned to assess for the primary endpoint in cohorts A and B, respectively. RESULTS: Twenty patients were enrolled and 19 treated (11 in cohort A; 8 in cohort B). Three patients on cohort A [27%; 95% confidence interval (CI), 8%-56%] and 1 on cohort B (12.5%; 90% CI, 0.6%-47%) achieved the primary endpoint. Two partial responses were observed in cohort A (18.2%; 90% CI, 3%-47%); none were observed in cohort B. The median TTP and OS was 3.3 (90% CI, 2.1-3.9 months) and 9.1 months (90% CI, 4.3-14.2 months), respectively, in all treated patients. CONCLUSIONS:
|
Authors | Richard D Carvajal, Donald P Lawrence, Jeffrey S Weber, Thomas F Gajewski, Rene Gonzalez, Jose Lutzky, Steven J O'Day, Omid Hamid, Jedd D Wolchok, Paul B Chapman, Ryan J Sullivan, Jerrold B Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R Antonescu, Michael C Heinrich, Boris C Bastian, Christopher L Corless, Jonathan A Fletcher, F Stephen Hodi |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 21
Issue 10
Pg. 2289-96
(May 15 2015)
ISSN: 1557-3265 [Electronic] United States |
PMID | 25695690
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | ©2015 American Association for Cancer Research. |
Chemical References |
- Antineoplastic Agents
- Pyrimidines
- Proto-Oncogene Proteins c-kit
- nilotinib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Brain Neoplasms
(drug therapy, genetics, secondary)
- Disease Progression
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Melanoma
(drug therapy, genetics, secondary)
- Middle Aged
- Proto-Oncogene Proteins c-kit
(genetics)
- Pyrimidines
(therapeutic use)
- Skin Neoplasms
(drug therapy, genetics, pathology)
- Treatment Outcome
|